ArticleTherapeutic advances in medical oncology2025

Camrelizumab plus SOX chemotherapy as adjuvant therapy for pathological stage III gastric or gastroesophageal junction adenocarcinoma: a prospective, multicenter, single-arm, phase II trial.

Hailong Jin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.